These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35973527)

  • 21. Predicting inadequate treatment response in children with chronic spontaneous urticaria.
    Park YM; Oh MS; Kwon JW
    Pediatr Allergy Immunol; 2020 Nov; 31(8):946-953. PubMed ID: 32643837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
    Cakmak ME; Yeğit OO; Öztop N
    Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience.
    Gimenez-Arnau A; Bartra J; Ferrer M; Jauregui I; Borbujo J; Figueras I; Muñoz-Bellido FJ; Pedraz J; Serra-Baldrich E; Tejedor-Alonso MA; Velasco M; Terradas P; Labrador M
    J Investig Allergol Clin Immunol; 2022 Jun; 32(3):191-199. PubMed ID: 33349612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal clinical important difference (MCID) of the Thai Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).
    Kulthanan K; Chularojanamontri L; Tuchinda P; Rujitharanawong C; Baiardini I; Braido F
    Asian Pac J Allergy Immunol; 2016 Jun; 34(2):137-45. PubMed ID: 27007835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Headache deteriorates the quality of life in children with chronic spontaneous urticaria.
    Filiz S; Kutluk MG; Uygun DFK
    Allergol Immunopathol (Madr); 2019; 47(3):254-259. PubMed ID: 30686612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire - CU-Q2oL.
    Dias GA; Pires GV; Valle SO; França AT; Papi JA; Dortas SD; Levy SA; Baiardini I; Canonica GW
    Allergy; 2011 Nov; 66(11):1487-93. PubMed ID: 21899558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
    Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study).
    Jauregui I; Gimenez-Arnau A; Bartra J; Labrador-Horrillo M; de Frutos JO; Silvestre JF; Sastre J; Velasco M; Ferrer M; Ballesteros C; Valero A
    Health Qual Life Outcomes; 2019 Jan; 17(1):23. PubMed ID: 30704532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice.
    Baiardini I; Braido F; Molinengo G; Caminati M; Costantino M; Cristaudo A; Crivellaro M; Ferrucci SM; Gallo R; Giorgis V; Legori A; Loera B; Martignago I; Marzano AV; Morrone A; Parente R; Parodi A; Parolo A; Peveri S; Pigatto P; Radice A; Ridolo E; Rolla G; Roncallo C; Rossi O; Savi E; Senna G; Triggiani M; Canonica GW
    J Allergy Clin Immunol Pract; 2018; 6(1):208-218. PubMed ID: 28803183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urticaria from the Neurodermatological Perspective: A Temporal Analysis of Urticaria and Cognition.
    A T; Lambrou GI; Kyritsi A; Geronikolou SA; Nikolaidou E; Katsarou A; Chatziioannou A; Stratigos A; Rigopoulos D
    Adv Exp Med Biol; 2021; 1339():209-220. PubMed ID: 35023108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study.
    Thomsen SF; Pritzier EC; Anderson CD; Vaugelade-Baust N; Dodge R; Dahlborn AK; Vestergaard C
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1048-1055. PubMed ID: 28294420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).
    Valero A; Herdman M; Bartra J; Ferrer M; Jáuregui I; Dávila I; del Cuvillo A; Montoro J; Mullol J; Sastre J; Canonica GW; Baiardini I
    J Investig Allergol Clin Immunol; 2008; 18(6):426-32. PubMed ID: 19123433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-Related Utility of EQ-5D in Korean Adults With Chronic Urticaria: Mapping From Urticaria Outcome Measures.
    Lee MS; Yoon J; Kim J; Shin YS; Park HS; Lee HY; Ye YM
    Allergy Asthma Immunol Res; 2020 Jul; 12(4):599-607. PubMed ID: 32400127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria - Results from the validation of the Polish Urticaria Control Test.
    Brzoza Z; Badura-Brzoza K; Maurer M; Hawro T; Weller K
    World Allergy Organ J; 2022 Mar; 15(3):100635. PubMed ID: 35399816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of COVID-19 pandemic on the management of patients with chronic urticaria: An observational two-center study from Turkey.
    Erdem Y; Polat Ekinci A; Altunay IK; Sivaz O; Inal S; Gokalp MO; Pehlivan G; Özkaya E
    Dermatol Ther; 2021 Jan; 34(1):e14652. PubMed ID: 33301190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Turkish version of the chronic urticaria quality of life questionnaire: cultural adaptation, assessment of reliability and validity.
    Kocatürk E; Weller K; Martus P; Aktas S; Kavala M; Sarigul S; Baiardini I; Canonica GW; Brzoza Z; Kalogeromitros D; Maurer M
    Acta Derm Venereol; 2012 Jul; 92(4):419-25. PubMed ID: 21918791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.